DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer
NCT06173310
·
clinicaltrials.gov ↗
NA
Phase
RECRUITING
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Borderline-resectable Pancreatic Cancer
Interventions
DEVICE:
Point-of-care Portable Perfusion Phantom (P4)
Sponsor
Ohio State University